Abstract
Myopericarditis associated with COVID-19 mRNA vaccines has been recognized as an uncommon adverse reaction, especially among young, healthy adult males. Eosinophilic myocarditis is a rare form of inflammation reflecting a hypersensitivity reaction following an inciting event commonly caused by drugs including vaccines. Eosinophilic myocarditis, a subtype of myocarditis, is characterized by eosinophilic myocardial infiltrates. It is usually accompanied by systemic eosinophilia in the form of a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and is rarely associated with myocyte fibrosis and/or necrosis. In this report, we present a case of biopsy-proven eosinophilic myocarditis in a 24-year-old male patient, likely secondary to COVID-19 mRNA vaccination. To our knowledge, this is the first report to describe delayed eosinophilic myocarditis following the COVID-19 mRNA vaccine. Clinicians should be aware of possible delayed presentation to avoid associated morbidity.
Cite
CITATION STYLE
Janga, C., Patel, T., Al Hennawi, H., Atam, S., Shah, S., Naeem, I., … Haas, D. C. (2023). Delayed presentation of biopsy-proven eosinophilic myocarditis following COVID-19 mRNA vaccine. Global Cardiology Science and Practice, 2023(2). https://doi.org/10.21542/gcsp.2023.10
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.